Omeros (NASDAQ:OMER) Upgraded at Wall Street Zen
by Renee Jackson · The Cerbat GemWall Street Zen upgraded shares of Omeros (NASDAQ:OMER – Free Report) from a sell rating to a hold rating in a report issued on Saturday morning.
A number of other equities analysts also recently commented on OMER. D. Boral Capital reiterated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday, January 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. Finally, HC Wainwright lifted their price target on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.33.
Check Out Our Latest Research Report on Omeros
Omeros Stock Performance
NASDAQ:OMER opened at $10.89 on Friday. The company has a market capitalization of $784.08 million, a price-to-earnings ratio of -21.78 and a beta of 2.53. Omeros has a one year low of $2.95 and a one year high of $17.65. The stock has a 50-day simple moving average of $11.34 and a 200 day simple moving average of $9.96.
Omeros (NASDAQ:OMER – Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $3.69. On average, equities research analysts forecast that Omeros will post -3.09 EPS for the current fiscal year.
Insider Buying and Selling
In other Omeros news, CAO David J. Borges sold 30,000 shares of Omeros stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.90% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Omeros
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC boosted its stake in Omeros by 13.0% in the fourth quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock valued at $11,817,000 after acquiring an additional 79,263 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Omeros in the fourth quarter valued at approximately $159,000. Invesco Ltd. boosted its stake in Omeros by 26.8% in the fourth quarter. Invesco Ltd. now owns 154,782 shares of the biopharmaceutical company’s stock valued at $2,658,000 after acquiring an additional 32,707 shares during the period. Virtus Investment Advisers LLC acquired a new position in Omeros in the fourth quarter valued at approximately $450,000. Finally, Wellington Management Group LLP boosted its stake in Omeros by 4.2% in the fourth quarter. Wellington Management Group LLP now owns 202,617 shares of the biopharmaceutical company’s stock valued at $3,480,000 after acquiring an additional 8,170 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.
About Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.